Key result
This review summarizes present guidelines, recommendations, and ongoing trials regarding the timing, dosage, and duration of anticoagulation in patients with COVID-19.
Why the study?
There is no universal consensus regarding the timing, dosage, and duration of anticoagulation in COVID-19 or the need for postdischarge prophylaxis.
Does anticoagulation improve outcomes in patients with COVID-19?
Does anticoagulation improve outcomes in patients with COVID-19?
Answers are grounded in this paper and cite their sources.
This review highlights the lack of universal consensus on the timing, dosage, and duration of anticoagulation in COVID-19 and aims to provide a comprehensive strategy based on current guidelines and trials.
Rising incidence of thromboembolism secondary to COVID-19 has become a global concern, with several surveys reporting increased mortality rates. Thrombogenic potential of the SARS-CoV-2 virus has been hypothesised to originate from its ability to produce an exaggerated inflammatory response leading to endothelial dysfunction. Anticoagulants have remained the primary modality of treatment of thromboembolism for decades. However, there is no universal consensus regarding the timing, dosage and duration of anticoagulation in COVID-19 as well as need for postdischarge prophylaxis. This article seeks to review the present guidelines and recommendations as well as the ongoing trials on use of anticoagulants in COVID-19, identify discrepancies between all these, and provide a comprehensive strategy regarding usage of these drugs in the current pandemic.
No takes yet. Share an insight, caveat, or question.
Chandra et al. (2021) conducted a review in COVID-19 and thromboembolism. Anticoagulants was evaluated. This review summarizes present guidelines, recommendations, and ongoing trials regarding the timing, dosage, and duration of anticoagulation in patients with COVID-19.
Synapse has enriched 10 related papers. Consider them for comparative context: